No Picture
News

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer

– Guidelines include TAILORx-defined cutoff of 26 for determining chemotherapy benefit in node-negative disease, and recommend that more women with limited nodal involvement may avoid chemotherapy- Oncotype DX® test recommended based on prospective lan… […]

No Picture
News

NuVasive SpineTRACK Registry Successfully Meets 2018 Medicare Reporting Requirements For Merit-based Incentive Payments System

SpineTRACK represents the only industry-sponsored spine registry that qualified providers to receive positive payment adjustments up to seven percent on all Medicare reimbursements in 2020

SAN DIEGO, May 30, 2019 /PRNewswire/ — NuVasive, Inc. (NASDA… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy

SAN DIEGO, May 21, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet p… […]

No Picture
News

Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting

– Results Confirm the Posterior Trajectory as an Additional Surgical Delivery Route for VY-AADC in Patients with Parkinson’s Disease- Treatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Tim… […]

No Picture
News

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients with Motor Fluctuations

– More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer- Data Analysis from the BIPARK-1 and BIPARK-2 Phase III Studies Highlighted as an Oral Presentation at the 2019 American … […]

No Picture
News

New Evidence Shows Brain Recovery after Traumatic & Spontaneous Intracerebral Hemorrhage using NICO Minimally Invasive BrainPath Approach

SAN DIEGO, April 23, 2019 /PRNewswire/ — The use of Minimally Invasive Parafascicular Surgery (MIPS) techniques for removal of traumatic hematoma is encouraging, innovative and promising. Those are the insights from Julian Bailes, MD, Chair of the … […]

No Picture
News

Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress(TM) 2019

Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8%88% of Patients Receiving VK2809 Experienced >= 30% Reduction in Liver Fat Content at 12 Weeks, Including all Patients Re… […]